Parenteral nutrition-associated liver disease: a retrospective study of ursodeoxycholic Acid use in neonates.
OBJECTIVE
To verify the effect of ursodeoxycholic acid (UDCA) on the duration of neonatal parenteral nutrition-associated liver disease.


METHODS
Retrospective cohort study of neonates in intensive care between 2004 and 2007 presenting with parenteral nutrition-associated liver disease.


RESULTS
Of 118 eligible infants, 64 received UDCA. Cholestasis lasted longer in the UDCA group (79 vs. 50 days, p=0.001). However, treatment was delayed for a median of 24 days after cholestasis onset. Multivariate Cox regression analysis showed no association between UDCA and cholestasis duration. The rate of decline of conjugated bilirubin was greater in treated patients (median 0.084 mg/dL/day vs. 0.60 mg/dL/day; p=0.009) and weight gain was greater (22.8 vs. 17.7 g/kg/day, p=0.010).


CONCLUSIONS
UDCA therapy was not associated with the duration of parenteral nutrition-associated liver disease. A delay in treatment initiation might explain this result. UDCA therapy was associated with a faster decline of conjugated bilirubin and greater weight gain.
Department of Pharmacy, CHU Sainte-Justine, Montreal, Canada.
Maxime
M
Thibault
Department of Pharmacy, CHU Sainte-Justine, Montreal, Canada.
Jessica
J
McMahon
Department of Pharmacy, CHU Sainte-Justine, Montreal, Canada.
Guillaume
G
Faubert
Department of Pharmacy, CHU Sainte-Justine, Montreal, Canada.
Julie
J
Charbonneau
Department of Pharmacy, CHU Sainte-Justine, Montreal, Canada.
Josianne
J
Malo
Department of Pharmacy, CHU Sainte-Justine, Montreal, Canada ; Faculty of Pharmacy, University of Montreal, Montreal, Canada.
Ema
E
Ferreira
Faculty of Medicine, University of Montreal, Montreal, Canada.
Ibrahim
I
Mohamed
hyperbilirubinemia; infant; liver disease; neonate; parenteral nutrition; premature; ursodeoxycholic acid